Fierce Pharma

APRIL 20, 2023

Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028 zbecker Thu, 04/20/2023 - 10:19

130

130

European Pharmaceutical Review

OCTOBER 24, 2023

billion in 2028, according to a report by Arizton. percent up to 2028. percent between the forecast period: 2023 and 2028. percent between the forecast period 2023-2028. Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 Having been valued at $27.04 percent in 2022.

Pharmaceutical 118

Pharmaceutical Marketing Medicine Pharmaceutical Sales 118

European Pharmaceutical Review

OCTOBER 10, 2024

A draft joint EU network strategy to 2028 has been published by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). The overarching theme of our updated strategy to 2028 is that of change – rapid, somewhat unpredictable but nonetheless full of promise.

Medicine 98

Medicine Networking Competition Pharmaceutical 98

European Pharmaceutical Review

SEPTEMBER 6, 2023

million by 2028, with a CAGR of 7.3 percent from 2023 to 2028. Between 2023 to 2028, the research suggested that a greater focus on drug development, growing requirement for spectroscopy via cloud-based platforms, alongside the industry’s need for precise and effective analytical methods, will drive the market.

Marketing 98

Marketing Distribution Pharmaceutical products Pharmaceutical 98

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105

Sales Marketing Prescription Pharma 105

Fierce Pharma

SEPTEMBER 27, 2023

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. The partners plan to make Ryzumvi available in the U.S.

Pharmacology 232

Pharmacology FDA Sales 232

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028.

Medicine 98

Medicine Marketing Safety Pharmaceutical 98

Fierce Pharma

FEBRUARY 8, 2024

Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

Sales 189

Sales Pharma Marketing 189

PharmaTech

OCTOBER 8, 2024

According to the annual survey, four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which are expected to have 45% of all CMO capacity in Asia.

52

52

Pharmaceutical Technology

OCTOBER 25, 2024

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Manufacturing 98

Manufacturing 98

European Pharmaceutical Review

MARCH 12, 2025

MSD shared that a further $8 billion of US capital investment is anticipated by 2028. The intention is to widen its manufacturing and R&D capabilities and boost recruitment in the US.

Manufacturing 52

Manufacturing Training Recruitment Pharmaceutical 52

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

Marketing 98

Marketing Pharmaceutical Management Leads 98

European Pharmaceutical Review

MARCH 25, 2025

MSD intends to commit a further $8 billion of US capital investment by 2028, the firm shared. The company highlighted that it plans to increase its manufacturing and R&D capabilities and recruitment in the US. The post MSD to advance investigational Lp(a) inhibitor in nearly $2b deal appeared first on European Pharmaceutical Review.

Manufacturing 52

Manufacturing Pharma Recruitment Pharmaceutical 52

PharmaTech

MARCH 24, 2025

The EU medicines agencies network strategy, EMANS, is an update of the five-year strategy previously developed to cover the period 2021 to 2025.

Networking 52

Networking Medicine 52

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical 98

Pharmaceutical Marketing Manufacturing Medicine 98

Pharmaceutical Technology

DECEMBER 18, 2024

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.

Marketing 59

Marketing Management Pharmaceutical 59

World of DTC Marketing

SEPTEMBER 9, 2021

Prescription drug costs are only a small part of healthcare costs, and by 2028 U.S. But even though the government may be saving money, ordinary taxpayers probably won’t see any discounts. healthcare spending will reach $6.2 trillion and account for almost 20% of the GDP. Several factors contribute to the higher cost of U.S. healthcare.

Healthcare 222

Healthcare Healthcare Government Insurance 222

PharmExec

MARCH 24, 2025

The facility, which is set to open amid Biogens 50th anniversary, will integrate research and development, technical operations, and commercial teams into one location.

52

52

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

Leads 58

Leads Medicine Marketing 58

World of DTC Marketing

MARCH 17, 2021

Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6 million, the company disclosed in a proxy filing” No biosimilar will take on Humira’s $16 billion in 2020 U.S.

Pharma 186

Pharma Competition Prescription Sales 186

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

Manufacturing 52

Manufacturing Marketing 52

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

Prescription 52

Prescription Medicine Pharma 52

Pharmaceutical Technology

JANUARY 15, 2024

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

FDA 59

FDA 59

InCrowd

AUGUST 11, 2022

Based on their responses it seems that while these tests are growing in popularity with the market expected to surpass $10B in 2028 , Genetic Counselors reported concerns over patients using them as an indicator for health in addition to questions over the validity of the results patients receive.

Healthcare Provider 130

Healthcare Provider Consulting Healthcare Healthcare 130

Pharmaceutical Commerce

JANUARY 18, 2024

The predicted value is largely driven by manufacturers' prioritization of brand protection.

Marketing 52

Marketing Manufacturing 52

PharmaTech

OCTOBER 11, 2024

The draft joint network strategy for the EU until 2028 will be open for public consultation until Nov. 30, 2024.

Consulting 52

Consulting Networking 52

European Pharmaceutical Review

APRIL 15, 2024

The new investment in the Holly Springs facility will “add 8 x 20,000 L mammalian cell culture bioreactors by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment”.

Manufacturing 98

Manufacturing Biopharma Networking Pharmaceutical 98

European Pharmaceutical Review

NOVEMBER 28, 2024

Without sufficient support systems and experienced reviewers, the implementation timelines were extended, with final compliance dates now pushed to December 2028 (from May 2024 originally).

Medical 105

Medical Government Safety Management 105

European Pharmaceutical Review

JUNE 5, 2024

billion in 2028. A report by the Business Research Company predicts that the small molecule injectable drugs market will value $355.14 As such, the compound annual growth rate (CAGR) is expected to be 12.8 percent up to this period.

Marketing 97

Marketing Pharmaceutical Patients 97

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Paxlovid, the company’s small-molecule Covid-19 oral therapy, was shown to reduce Covid-19 infections by 32% in adults and is forecast to be the top-selling drug by total sales, generating $81bn between 2021 and 2028. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

European Pharmaceutical Review

NOVEMBER 14, 2023

Europe’s pharmaceutical packaging market to value over $35bn by 2028 The post USP General Chapter <660>—Glass revised appeared first on European Pharmaceutical Review. The PD EC plans to publish another major revision to <660> to modernise the testing procedures in the chapter, USP stated.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Distribution Food 105

European Pharmaceutical Review

OCTOBER 16, 2023

The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20 percent between 2023 and 2028, the contract development and manufacturing organisation (CDMO) highlighted. Enhancing manufacturing capabilities The bioconjugates market is currently valued at $33 billion according to research by Lonza.

Manufacturing 105

Manufacturing Marketing Networking Pharmaceutical 105

European Pharmaceutical Review

DECEMBER 19, 2023

The workplan, which runs until 2028, will help the European medicines regulatory network (EMRN) embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health.

Pharma 105

Pharma Networking Medicine Ethics 105

Pharmaceutical Technology

JANUARY 9, 2024

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

52

52

European Pharmaceutical Review

NOVEMBER 24, 2023

These activities are expected to be completed incrementally between 2026 to 2028, the company stated. While the current production facility in Chartres, France, employ around 1,600 people, once the new multi-product facilities are in operation, over 500 new jobs will be created to manage continuous production activities.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 98

European Pharmaceutical Review

AUGUST 22, 2023

Between 2023-2028, the global bioprocess containers market is anticipated to see strong growth. A market report by Research and Markets considers this to be mainly due to the higher demand for automation and machine learning in the biopharmaceutical industry.

Marketing 98

Marketing Manufacturing Leads Pharmaceutical 98

Pharmaceutical Technology

JANUARY 30, 2023

These are forecast to generate $264 billion in sales between 2021 and 2028. The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028.

Sales 52

Sales Leads Competition Medicine 52